Cue Biopharma Inc (1UC.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
As of 08:18AM CEST. Market open.
| Previous close | 1.7500 |
| Open | 1.5900 |
| Bid | 1.5900 x N/A |
| Ask | 1.6000 x N/A |
| Day's range | 1.5900 - 1.5900 |
| 52-week range | 1.2500 - 4.1360 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Cue Biopharma First Quarter 2024 Earnings: Beats Expectations
Cue Biopharma ( NASDAQ:CUE ) First Quarter 2024 Results Key Financial Results Revenue: US$1.72m (up by US$1.53m from 1Q...
- Zacks
Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks
Cue Biopharma (CUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Zacks
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now
Cue Biopharma (CUE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
© 2024 Yahoo. All rights reserved.